Explore the evolving role of oral SERDs in HR-positive, HER2-negative advanced breast cancer. Hear expert perspectives on ESR1 mutation testing, treatment selection and sequencing, emerging combination strategies, circulating tumor DNA (ctDNA) monitoring, and safety considerations that may inform individualized treatment decisions.

Visit https://suitehome.atpointofcare.com/library/2760.12/page/0 to view the activity and CME/CE information, download the transcript, and complete the posttest and evaluation to earn CME/CE credit.

This podcast is powered by Pinecast.

Stay ahead of evolving endocrine resistance in HR-positive, HER2-negative advanced breast cancer. Discover how ESR1 mutations are reshaping treatment decisions, and explore expert perspectives on mutation testing, oral SERDs, and emerging serial monitoring strategies that may help identify resistance earlier and inform individualized patient care.

Visit https://suitehome.atpointofcare.com/library/2760.11/page/0 to view the activity and CME/CE information, download the transcript, and complete the posttest and evaluation to earn CME/CE credit.

This podcast is powered by Pinecast.

RAS-targeted therapies are reshaping the treatment landscape for pancreatic ductal adenocarcinoma, creating new challenges in understanding the mechanisms and potential clinical applications of allele-specific, pan-KRAS, and pan-RAS inhibitors. Join Dr. Eileen O’Reilly and Dr. Margaret Tempero as they explore the evolving RAS therapeutic pipeline and discuss how these emerging strategies may inform future treatment decisions.

Visit https://suitehome.atpointofcare.com/library/2746.02/page/0 to view the activity and CME/CE information, download the transcript, and complete the posttest and evaluation to earn CME/CE credit.

This podcast is powered by Pinecast.

As biomarker-directed therapies expand in pancreatic ductal adenocarcinoma, comprehensive genomic profiling is becoming increasingly important for identifying actionable alterations and informing treatment decisions. Join Dr. Eileen O’Reilly and Dr. Margaret Tempero as they discuss when and how to perform genomic profiling, interpret key findings, and address practical challenges to obtaining clinically useful molecular information.

Visit https://suitehome.atpointofcare.com/library/2746.01/page/0 to view the activity and CME/CE information, download the transcript, and complete the posttest and evaluation to earn CME/CE credit.

This podcast is powered by Pinecast.

This final episode of a three-part expert-led podcast series explores the emerging toxicity landscape as immunotherapy- and antibody-drug conjugate–based regimens enter the treatment of muscle-invasive bladder cancer. Faculty will discuss the mechanistic basis for these side effects, practical monitoring and management strategies, and the multidisciplinary coordination needed among oncology, urology, and subspecialists to navigate them safely.

Visit https://suitehome.atpointofcare.com/library/2744.03/page/0 to view the activity and CME/CE information, download the transcript, and complete the posttest and evaluation to earn CME/CE credit.

This podcast is powered by Pinecast.

This expert-led podcast explores practical treatment selection in the evolving perioperative landscape for muscle-invasive bladder cancer. Faculty will discuss how to assess treatment eligibility, navigate immunotherapy-based and antibody-drug conjugate–based options, and coordinate care across specialties to support timely, individualized treatment decisions.

Visit https://suitehome.atpointofcare.com/library/2744.02/page/0 to view the activity and CME/CE information, download the transcript, and complete the posttest and evaluation to earn CME/CE credit.

This podcast is powered by Pinecast.

This expert-led podcast explores the rapidly evolving perioperative treatment landscape in muscle-invasive bladder cancer. Faculty will discuss pivotal data from NIAGARA, KEYNOTE-905, and KEYNOTE-B15, and consider how recent advances are expanding systemic treatment options, including for patients who are cisplatin-ineligible, and reshaping perioperative care.

Visit https://suitehome.atpointofcare.com/library/2744.01/page/0 to view the activity and CME/CE information, download the transcript, and complete the posttest and evaluation to earn CME/CE credit.

This podcast is powered by Pinecast.

Given the diversity of peripheral T-cell lymphoma (PTCL) subtypes, clinicians may need guidance choosing which therapy is most appropriate for each subtype. Join Dr. Steven Horwitz and Theresa Davey, PA-C, for a discussion of the PTCL treatment landscape and the evidence for matching epigenetic therapies to specific PTCL subtypes.

Visit https://www.atpointofcare.com/library/2736.02/page/0 to view the activity and CME/CE information, download the transcript, and complete the posttest and evaluation to earn CME/CE credit.

This podcast is powered by Pinecast.